Replies to post #202524 on Biotech Values

[marthambles]

I think it's on or off, but little chance of being able to make it 25%, 50% or 75% on. That's a level of control that will be very difficult to achieve.

Above my pay grade to quibble, however I would point out the following from BLCM's website:

In addition to using our CaspaCIDe technology for the substantial elimination of cellular therapy, like an “off” switch, we are studying partial elimination of a cellular therapy, like a “dimmer” switch, by delivering reduced doses of rimiducid. We observed the dose response to rimiducid by measuring the viability of BPX-501 cells in culture following the addition of increasing amounts of rimiducid to the culture medium, as well as by measuring the survival of BPX-501 cells in vivo in immune-deficient mice following injection of increasing doses of rimiducid. In these preclinical studies, rimiducid rapidly and consistently reduced or eliminated CaspaCIDe-containing cells in a dose-dependent manner.

[DFRAI]

Poorgradstudent

I can't argue with you...because I dont have the knowledge ...even to try and post here the relevant info.

This is a study to a 3rd generation CAR...or sleeping beauty actually

https://www.researchgate.net/publication/304195746_Immunotherapy_of_acute_leukemia_by_chimeric_antigen_receptor-modified_lymphocytes_using_an_improved_Sleeping_Beauty_transposon_platform

I have read a lot and the IV ziop board has some good info as well as the publications out there...some studies also show under MD Anderson and other corraborators etc

I really think that Dr. Cooper is well regarded and has first hand knowledge of CAR, NK, TCR and if you would read some of his work and publications - i think that you would agree as well.

I have been trying to raise awareness on the biotech board as to this company, recent modifications to their agreement with XON which portend to a large deal for ZIOP, buyout etc

With regards to IL-12 - its been in the public domain for 20-30 years and yet nobody has been able to control the CRS etc....ZIOP did in their glioma studies and reversed grade 3-4 toxicities etc

http://www.ziopharm.com/content/02-pipeline/03-presentations-publications/3-asgct/1-regulated-expression-of-il-12-as-gene-therapy-concomitant-with-blockade-of-pd-1-for-treatment-of-glioma/asgct2016re.pdf

Md Anderson IP and other
http://www.investorvillage.com/smbd.asp?mb=16353&mn=11901&pt=msg&mid=14620320

Improving persistance of T cells in CAR thru IL15

http://www.investorvillage.com/smbd.asp?mb=16353&mn=46725&pt=msg&mid=15835364


Best wishes...